This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Members of the Sicilian Gambit, Search for Related Content PubMed PubMed Citation Articles by Members of the Sicilian Gambit, Related Collections Electrophysiology Cardiovascular Pharmacology ACE/Angiotension receptors Animal models of human disease Arrythmias-basic studies Physiological and pathological control of gene expression Arrhythmias, clinical electrophysiology, drugs Receptor pharmacology

(Circulation. 2001;104:2865.)
© 2001 American Heart Association, Inc.

Current Perspective

New Approaches to Antiarrhythmic Therapy, Part I

Emerging Therapeutic Applications of the Cell Biology of Cardiac Arrhythmias

Members of the Sicilian Gambit

Correspondence to Michael R. Rosen, MD, Gustavus A. Pfeiffer Professor of Pharmacology, Professor of Pediatrics, Director, Center for Molecular Therapeutics, College of Physicians & Surgeons of Columbia University, Department of Pharmacology, 630 West 168 Street, H7W-321, New York, NY 10032. E-mail mrr1{at}columbia.edu

Cardiac arrhythmias complicate many diseases affecting the heart and circulation, and they incorporate a multiplicity of underlying mechanisms. The evolution of scientific knowledge has made the complex changes produced by cardiovascular disease sufficiently understood at the organ, cellular, and molecular levels such that there is a diversity of therapeutic targets for pharmacological therapy and/or prevention. Moreover, the approach of rational drug design in mechanism-specific and disease-specific fashions facilitates the targeting of therapy using the methods of molecular, structural, and translational biology. Additional approaches, using similar drug design strategies but based on gene therapy and transcriptional and translational modification, are on the horizon. Hence, there is reason to be optimistic regarding the design, testing, and clinical availability of novel antiarrhythmic therapies.

Key Words: molecular biology • gene therapy • genes • electrophysiology • pharmacology

This article has been cited by other articles:

				C. E. Clancy and R. S. Kass Inherited and Acquired Vulnerability to Ventricular Arrhythmias: Cardiac Na+ and K+ Channels Physiol Rev, January 1, 2005; 85(1): 33 - 47. [Abstract] [Full Text] [PDF]

				C. E. Clancy and R. S. Kass Theoretical Investigation of the Neuronal Na+ Channel SCN1A: Abnormal Gating and Epilepsy Biophys. J., April 1, 2004; 86(4): 2606 - 2614. [Abstract] [Full Text] [PDF]

				Y.-J. Chen, Y.-C. Chen, H.-I Yeh, C.-I Lin, and S.-A. Chen Electrophysiology and Arrhythmogenic Activity of Single Cardiomyocytes From Canine Superior Vena Cava Circulation, June 4, 2002; 105(22): 2679 - 2685. [Abstract] [Full Text] [PDF]

				H. A. Fozzard and J. W. Kyle Do Defects in Ion Channel Glycosylation Set the Stage for Lethal Cardiac Arrhythmias? Sci. Signal., April 30, 2002; 2002(130): pe19 - pe19. [Abstract] [Full Text] [PDF]